Adage Capital Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Adage Capital Partners’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.36M	Sell	344,315 -204,685	-37%	-$2.32M	0.01%	783
2025 Q4	$4.49M	Buy	549,000 +101,634	+23%	+$1.17M	0.01%	774
2025 Q3	$5.37M	Buy	447,366 +81,966	+22%	+$862K	0.01%	726
2025 Q2	$3.71M	Buy	+365,400	New	+$2.45M	0.01%	729
2025 Q1	–	Sell	-500,000	Closed	-$4.04M	–	916
2024 Q4	$4.04M	Sell	500,000 -75,000	-13%	-$688K	0.01%	735
2024 Q3	$5.89M	Sell	575,000 -205,400	-26%	-$2.03M	0.01%	694
2024 Q2	$5.52M	Sell	780,400 -250,000	-24%	-$2.24M	0.01%	699
2024 Q1	$14.2M	Buy	+1,030,400	New	+$12.2M	0.03%	538

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Adage Capital Partners's ORIC Position: Q1 2026 in Review

Adage Capital Partners reduced its Oric Pharmaceuticals (ORIC) stake by 37% in Q1 2026, selling an estimated $2.32M and leaving 344,315 shares worth $4.36M. The position accounts for 0.01% of the portfolio, ranked #783.

Adage Capital Partners first reported a position in ORIC in Q1 2024 and has held it in 8 quarters since. The position peaked at $14.2M in Q1 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Adage Capital Partners held 344,315 shares of Oric Pharmaceuticals worth $4.36M as of Q1 2026.
Adage Capital Partners sold 204,685 Oric Pharmaceuticals shares in Q1 2026, an estimated $2.32M.
Oric Pharmaceuticals made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #783 holding.
Adage Capital Partners first reported a position in Oric Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Adage Capital Partners's Oric Pharmaceuticals position peaked at $14.2M in Q1 2024.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.